Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer

Agriculture & Biology

• doxorubicin 70%
• breast neoplasms 65%
• phosphotransferases (kinases) 49%
• neoplasms 43%
• phosphorylation 12%
• cells 11%
• therapeutics 11%
• non-specific protein-tyrosine kinase 11%
• cancer therapy 10%
• cyclins 8%
• autophagy 8%
• small interfering RNA 8%
• drug therapy 7%
• mitosis 6%
• apoptosis 6%
• neoplasm cells 6%
• animal models 6%
• Western blotting 6%
• protein synthesis 5%
• phenotype 4%

Medicine & Life Sciences

• Elongation Factor 2 Kinase 100%
• Doxorubicin 52%
• Breast Neoplasms 36%
• Growth 28%
• Neoplasms 18%
• Peptide Elongation Factor 2 10%
• Down-Regulation 10%
• Phosphorylation 9%
• Focal Adhesion Protein-Tyrosine Kinases 8%
• Cyclin D1 7%
• MCF-7 Cells 7%
• Mitosis 7%
• Autophagy 6%
• Heterografts 6%
• Small Interfering RNA 5%
• Western Blotting 4%
• Therapeutics 4%
• Apoptosis 4%
• Phenotype 4%
• Drug Therapy 4%
• In Vitro Techniques 3%
• Proteins 2%

Chemistry

• Doxorubicin 59%
• Silencing RNA 37%
• Western Blotting 36%
• Sensitization 30%
• Protein Synthesis 29%
• Resistance 17%